Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.

"Competing interests: HIB has received grants and consulting fees from Novartis; ICP has received payment honoria for lectures, presentations, speakers bureaus from Novartis; MH has received payment for participation on data safety monitoring board or advisory board from Novartis;GSS has received grants and consulting fees from Novartis; AVR has received consulting fees from Abbvie, Astra Zeneca, Eli Lilly, Novartis, Roche, UCB; payment/honoria for lectures, presentations, speakers bureaus from Abbvie, Eli Lilly, Novartis, Roche, SOBI; payment for participation on data safety monitoring board or advisory board from Eli Lilly; EZ has received grants or contracts from Novartis and Pfizer; payment/honoria for lectures, presentations, speakers bureaus from Abbvie, MSD, Novartis, Pfizer and Roche; has received support for attending meetings and/or travel from Abbvie, MSD, Novartis, Pfizer and Roche; Ruvie Martin, Xuan Zhu, Sarah Whelan and Luminita Pricop are employees and shareholders of Novartis; AM has received consulting fees from Aurinia, Bristol Myers and Squibb, Eli Lilly, EMD, Serono, Janssen, Pfizer and Roche; payment/ honoria for lectures, presentations, speakers bureaus from Aurinia, Bristol Myers and Squibb, Eli Lilly, EMD, Janssen, Pfizer, Roche and Serono; DJL has received grants and consulting fees from Astra Zeneca, Boehringer Ingelheim, GSK, Hoffman LaRoche, Novartis, and UBC; Nicolino Ruperto has received consulting fees from Ablynx, Amgen, Astrazeneca-Medimmune, Aurinia, Bayer, Bristol Myers and Squibb, Cambridge Healthcare Research (CHR), Celegene, Domain therapeutic, Eli Lilly, EMD Serono, GlaxoSmith and Kline, Idorsia, Janssen, Novartis, Pfizer, SOBI and UCB; payment/ honoria for lectures, presentations, speakers bureaus from Eli Lilly, GlaxoSmith and Kline, Pfizer, SOBI and UCB; has received payment for participation on data safety monitoring board or advisory board from Eli Lilly and Pfizer; has received funding from Bristol Myers and Squibb, Eli Lilly, F Hoffmann-La Roche, Novartis, Pfizer and SOBI."

"Funding: This study (ClinicalTrials.gov; NCT03031782) was sponsored by Novartis Pharma AG, Basel, Switzerland."

"Trial registration number NCT03031782."